Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer

被引：26

作者：

Baek, J. H.

Kim, J. G. ^{[1
]}

Jeon, S. B.

Chae, Y. S.

Kim, D. H.

Sohn, S. K.

Lee, K. B.

Choi, Y. J.

Shin, H. J.

Chung, J. S.

Cho, G. J.

Jung, H. Y.

Yu, W.

机构：

[1] Kyungpook Natl Univ, Dept Hematol Oncol, Taegu, South Korea

[2] Pusan Natl Univ Hosp, Dept Hematol Oncol, Pusan, South Korea

[3] Kyungpook Natl Univ, Dept Gen Surg, Taejon, South Korea

来源：

BRITISH JOURNAL OF CANCER | 2006年 / 94卷 / 10期

关键词：

capecitabine; chemotherapy; gastric cancer; irinotecan;

D O I：

10.1038/sj.bjc.6603093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The present study was conducted to evaluate the efficacy and safety of a combination regimen of capecitabine plus irinotecan in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received oral capecitabine 1000 mg m(-2) twice daily from day 1 to 14 and intravenous irinotecan 100 mg m(-2) on days 1 and 8, based on a 3-week cycle. Forty-one patients were enrolled in the current study, among whom 38 were assessable for efficacy and 40 assessable for toxicity. Three complete responses and 16 partial responses were confirmed, giving an overall response rate of 46.3%. At a median follow-up of 269 days, the median time to progression and overall survival were 5.1 and 8.6 months, respectively. Grade 3/4 neutropenia occurred in four patients and grade 3 febrile neutropenia was observed in two patients. Grade 3 diarrhoea and grade 2 hand-foot syndrome occurred in six patients and eight patients, respectively. The combination of capecitabine and irinotecan was found to be well tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as one of first-line treatment options for advanced gastric cancer.

引用

页码：1407 / 1411

页数：5

共 34 条

[1]

Ahn Myung Ju, 2003, Cancer Res Treat, V35, P407, DOI 10.4143/crt.2003.35.5.407

[2] CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma - Results of a Phase II study [J].

Ajani, JA ;

Baker, J ;

Pisters, PWT ;

Ho, L ;

Mansfield, PF ;

Feig, BW ;

Charnsangavej, C .

CANCER, 2002, 94 (03) :641-646

[3]

Ajani JA, 2001, ONCOLOGY-NY, V15, P52

[4] Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma [J].

Bajetta, E ;

Di Bartolomeo, M ;

Mariani, L ;

Cassata, A ;

Artale, S ;

Frustaci, S ;

Pinotti, G ;

Bonetti, A ;

Carreca, I ;

Biasco, G ;

Bonaglia, L ;

Marini, G ;

Iannelli, A ;

Cortinovis, D ;

Ferrario, E ;

Beretta, E ;

Lambiase, A ;

Buzzoni, R .

CANCER, 2004, 100 (02) :279-287

[5] Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer [J].

Blum, JL ;

Jones, SE ;

Buzdar, AU ;

LoRusso, PM ;

Kuter, I ;

Vogel, C ;

Osterwalder, B ;

Burger, HU ;

Brown, CS ;

Griffin, T .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :485-493

[6] Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer [J].

Boku, N ;

Ohtsu, A ;

Shimada, Y ;

Shirao, K ;

Seki, S ;

Saito, H ;

Sakata, Y ;

Hyodo, I .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :319-323

[7] A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity [J].

Borner, MM ;

Bernhard, J ;

Dietrich, D ;

Popescu, R ;

Wernli, M ;

Saletti, P ;

Rauch, D ;

Herrmann, R ;

Koeberle, D ;

Honegger, H ;

Brauchli, P ;

Lanz, D ;

Roth, AD .

ANNALS OF ONCOLOGY, 2005, 16 (02) :282-288

[8] Irinotecan in the treatment of gastric cancer [J].

Bugat, R .

ANNALS OF ONCOLOGY, 2003, 14 :37-40

[9]

CASSATA A, 2001, P AN M AM SOC CLIN, V20, pA144

[10]

Dank M, 2005, J CLIN ONCOL, V23, p308S

← 1 2 3 4 →